Johnson & Johnson is hoping that when it files for approval in the EU of esketamine nasal spray, the experimental therapy for treatment-resistant depression will be given accelerated assessment.
The June meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is under way this...






